Leukemic stem cells as a target for eliminating acute myeloid leukemia: Gaps in translational research.
Acute myeloid leukemia
Leukemic stem cells
Measurable residual disease
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
28
09
2021
revised:
29
04
2022
accepted:
11
05
2022
pubmed:
20
5
2022
medline:
22
6
2022
entrez:
19
5
2022
Statut:
ppublish
Résumé
Relapse is common in acute myeloid leukemia (AML) and thought to be due to resistance of underlying leukemic stem cells (LSCs) to current standard therapies, although a lack of tools to measure the quantity and quality of these cells in patients precludes the clinical testing of this concept. This review discusses the current knowledge of LSC properties and appraises strategies aimed to bring the therapeutic targeting of LSCs to the bedside to improve patient outcomes. We highlight pathways and targets of interest and summarize available information on drugs that might eradicate LSCs. Future research is needed to close identified gaps in knowledge and provide evidence for the clinical efficacy of LSC-directed therapies to support the development of treatments that eliminate residual disease and prevent relapse, thereby increasing the cure rates of patients with AML.
Identifiants
pubmed: 35588936
pii: S1040-8428(22)00134-2
doi: 10.1016/j.critrevonc.2022.103710
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103710Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.